Pramipexole with leuprolide: a treatment strategy for PGAD

Raj, Rajnish; Bhagat, Nisha

doi:10.18203/2319-2003.ijbcp20172757

Cited by 2 publications

(1 citation statement)

References 26 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pramipexole has been used in the past to treat PGAD. 6 Raj et al report on a case of PGAD that was successfully treated with a combination of pramipexole and leuprolide. Pramipexole has also been reported to be associated with the development of PGAD in another case report in a woman with Parkinson's syndrome.…”

Section: Etiologymentioning

confidence: 99%

The Use of Pramipexole to Treat Persistent Genital Arousal Disorder: A Case Report

Lynn

Grabenhorst²,

Komisaruk

et al. 2021

Sexual Medicine

View full text Add to dashboard Cite

Introduction: Persistent Genital Arousal Disorder (PGAD) is defined as "spontaneous, intrusive, and unwanted genital arousal (tingling, throbbing, pulsating) in the absence of sexual interest and desire" and traditionally causes marked distress, embarrassment and shame. PGAD may be caused by starting, discontinuing, or making adjustments in certain antidepressants or other medications. Aim: To report the case of a 36-year-old woman with PGAD, likely due to changes in her psychiatric medications, who was treated with pramipexole and experienced improvement in her PGAD symptoms. Methods: Patient self-report and literature review. Written informed consent was obtained from the patient.Main Outcome Measure: Improvement in PGAD symptoms. Results: Patient reported improvement in her symptoms by "90%" on a low dose of pramipexole, although higher doses exacerbated her symptoms. Conclusions: It is likely that an effective treatment window exists for the treatment of PGAD with drugs that possess the ability to exert their control of dopaminergic transmission. This includes direct acting receptor agonists like pramipexole, which produce feedback inhibition. Limitations to their efficacy then involve co-treatments that counteract their ability to exert a dampening effect on hyperstimulated dopamine transmission. It is recommended that clinicians be aware of drugs taken by patients to treat psychiatric disorders that could induce PGAD symptoms, drugs recently discontinued where a rebound effect could lead to PGAD symptoms, and drug mechanisms that could counteract the effect of treatments for PGAD.

show abstract

Section: Etiologymentioning

confidence: 99%